Replies to post #208399 on Biotech Values

[lgonber]

Very much expected news, but still important and Action trading 20% on news this morning. The shares have rise 12.57% since it confirmed exclusive talks with J&J on Dec. 21 but are more than 50% higher since takeover speculation first surfaced in late November.
Interesting they are spinning out the R&D, very "creative"

[DewDiligence]

JNJ issues revised PR re Actelion deal—correction pertains to the initial cash balance of the spun-out R&D company:

http://finance.yahoo.com/news/johnson-johnson-acquire-actelion-30-061800104.html

[DinoADZ]

There's an adition to it: ...and plans to spin out the company's research and development unit into a separate business for 1 billion swiss francs

http://www.pharmaceuticaldaily.com/johnson-johnson-buys-actelion-for-30-billion/

[DewDiligence]

JNJ-Actelion—This seems too easy, but it worked:

https://www.bloomberg.com/news/articles/2017-01-27/hedge-funds-track-j-j-private-jet-for-an-edge-on-actelion-score

[DewDiligence]

JNJ—FDA approves generic versions of Tracleer:

#FDA approved several first generics for a drug used to treat pulmonary arterial hypertension, which is a rare, progressive disorder characterized by high blood pressure in the arteries of the lungs. This drug is managed by a REMS. https://t.co/5VuPkSm4jW pic.twitter.com/mxhe7l6kQp

— Media Affairs (@FDAMedia) April 29, 2019